Recombinant Human Thrombopoietin Treatment Promotes Hematopoiesis Recovery in Patients with Severe Aplastic Anemia Receiving Immunosuppressive Therapy

Abstract EN

Objective.

To assess the effectiveness of recombinant human thrombopoietin (rhTPO) in severe aplastic anemia (SAA) patients receiving immunosuppressive therapy (IST).

Methods.

Eighty-eight SAA patients receiving IST from January 2007 to December 2012 were included in this retrospective analysis.

Of these, 40 subjects received rhTPO treatment (15000 U, subcutaneously, three times a week).

rhTPO treatment was discontinued when the platelet count returned to normal range.

Hematologic response, bone marrow megakaryocyte recovery, and time to transfusion independence were compared.

Results.

Hematologic response was achieved in 42.5%, 62.5%, and 67.5% of patients receiving rhTPO and 22.9%, 41.6%, and 47.9% of patients not receiving rhTPO at 3, 6, and 9 months after treatment, respectively (P = 0.0665, P = 0.0579, and P = 0.0847, resp.).

Subjects receiving rhTPO presented an elevated number of megakaryocytes at 3, 6, and 9 months when compared with those without treatment (P = 0.025, P = 0.021, and P = 0.011, resp.).

The time to platelet and red blood cell transfusion independence was shorter in patients who received rhTPO than in those without rhTPO treatment.

Overall survival rate presented no differences between the two groups.

Conclusion.

rhTPO could improve hematologic response and promote bone marrow recovery in SAA patients receiving IST.